Understanding Estrogen and c-Myc in Breast Cancer Treatment
Author Information
Author(s): Musgrove Elizabeth A., Sergio C. Marcelo, Loi Sherene, Inman Claire K., Anderson Luke R., Alles M. Chehani, Pinese Mark, Caldon C. Elizabeth, Schütte Judith, Gardiner-Garden Margaret, Ormandy Christopher J., McArthur Grant, Butt Alison J., Sutherland Robert L.
Primary Institution: Garvan Institute of Medical Research, Sydney, Australia
Hypothesis
How do estrogen-regulated genes relate to the effectiveness of tamoxifen therapy in breast cancer?
Conclusion
The study identifies gene signatures that can predict patient responses to tamoxifen, potentially revealing mechanisms of resistance.
Supporting Evidence
- Estrogen regulates cell growth primarily through c-Myc.
- Gene signatures can stratify patients into groups with differing outcomes.
- c-Myc-responsive genes are significantly involved in estrogen action.
- Cell cycle and cell growth signatures are independent predictors of tamoxifen response.
- Patients with high c-Myc activity may have distinct biology and treatment resistance.
Takeaway
This study looks at how certain genes affected by estrogen can help doctors understand which breast cancer patients will respond well to a treatment called tamoxifen.
Methodology
The researchers classified estrogen-regulated genes by function and analyzed their relationship to tamoxifen response using gene expression profiling.
Potential Biases
Potential biases may arise from the selection of patient cohorts and the methods used for gene expression analysis.
Limitations
The study may not account for all factors influencing treatment response, and the findings need validation in larger cohorts.
Participant Demographics
Participants were women with ER-positive breast cancer who received tamoxifen therapy.
Statistical Information
P-Value
0.001
Confidence Interval
95% CI 1.007–1.025
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website